Latest Conference Articles

Final overall survival data for PEACE-3 (NCT02194842) evaluating the combination of enzalutamide (Xtandi) and radium-223 (Xofigo) will be presented at the 2026 ASCO GU Cancers Symposium.

Anticipated findings from the LITESPARK-011 trial (NCT04586231) to be presented during the 2026 ASCO Genitourinary Cancers Symposium could shift second-line approaches in metastatic renal cell carcinoma.

Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 therapy.

Highlights from the 2026 ASCO Genitourinary Cancer Symposium featuring key presentations in bladder, kidney, prostate, and rare cancers.

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS following transplant.

At 33.6 months' follow-up, patients with standard-risk multiple myeloma had improved progression-free survival outcomes with ciltacabtagene autoleucel vs standard of care.

A retrospective study of tumor-infiltrating lymphocyte therapy showed that despite its benefit, many patients were unable to receive lifileucel.

Phase 1 data show EB103 delivers 100% complete responses at high dose with manageable toxicity, offering a safer, durable option for high-risk B-cell NHL.

Post hoc data suggest Orca-T may boost survival and cut non-relapse mortality after allogeneic stem cell transplant in MDS and leukemias, pending phase 3 validation.

A trial found that off-the-shelf TRX103 Tr1 cells were safe to use after a mismatched donor stem cell transplant, showing engraftment, dose-dependent expansion, and persistence.

Real-world data show over an 40% response rate for lifileucel TIL therapy, indicating that those treated earlier did better and fewer doses of IL-2 could be used effectively.

A phase 2 trial of acalabrutinib led to favorable response rates and tolerability in steroid-refractory chronic GVHD.

A trial of ustekinumab as graft-vs-host disease (GVHD) prophylaxis after hematopoietic cell transplant did not meet its primary end point but showed more favorable outcomes in patients who had myeloablative conditioning.

A real-world ciltacabtagene autoleucel (cilta-cel) study revealed a link between high lymphocyte peaks and failed bridging to parkinsonism and nonrelapse mortality, potentially guiding early intervention.

Dr. Mukherjee explores the future of antibody-drug conjugates in GI cancers, emphasizing precision medicine and targeted therapies for optimal patient outcomes.

Clinicians explore the shift towards earlier use of antibody-drug conjugates in GI oncology, aiming to enhance patient outcomes and treatment efficacy.

Explore the vital role of antibody-drug conjugates in precision oncology for GI malignancies, focusing on managing payload-dependent toxicities effectively.

Discover the latest advancements in pancreatic cancer treatment, including targeted therapies and next-generation sequencing, transforming patient care and outcomes.

Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing precision and patient outcomes.

New trial results reveal zanidatamab significantly improves survival in HER2-positive advanced gastroesophageal adenocarcinoma, challenging existing treatment standards.

Practice-changing 2025 breast cancer trial updates spotlight giredestrant, tucatinib maintenance, and ribociclib in key subtypes, boosting disease control with manageable safety.

A recent study reveals that combining mFOLFOX6 and bevacizumab with atezolizumab significantly enhances progression-free survival (PFS) in patients with metastatic colorectal cancer.

New research highlights the benefits of physical activity, particularly walking, in reducing cancer-related fatigue and enhancing quality of life for colorectal cancer survivors.

A new integrated treatment regimen significantly enhances PFS vs standard chemotherapy in metastatic pancreatic cancer.

Giredestrant shows lower treatment discontinuation rates compared to standard therapy and is being explored in combination with other drugs.

Explore how thalidomide derivatives enhance T-cell responses and combat exhaustion in multiple myeloma therapies for improved patient outcomes.

New research highlights nivolumab AVD as a promising new standard of care for advanced Hodgkin lymphoma, showing improved survival rates and tolerability.

Emerging evidence of the benefit of antibody-drug conjugates in diffuse large B-cell lymphoma continues to make a strong case for the agents to be used in earlier lines of therapy.

The HER2CLIMB-05 trial reveals tucatinib enhances progression-free survival in HER2-positive metastatic breast cancer, offering new hope for patients.